SEHSCT Cardio Team – Fastest First Patient Randomised for the MERCK VICTOR trial

October 6, 2023


The Victor study is A Pivotal Phase 3 Randomised, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction.

It is a Commercial Cardio trial sponsored by MERCK pharmaceuticals which aims to recruit 6,000 adults with chronic heart failure.

PI Dr Patrick Donelly and the SEHSCT Research Team were congratulated for screening and randomising their first patient. As the last site to be added to the study in the UK, SEHSCT achieved the shortest amount of time between their Site Ready declaration to First Patient Randomised.

What an achievement!

Congratulations to the entire SEHSCT Cardiovascular Research Team

To find out more about the VICTOR Trial click here.